Omeros Corporation - FDA Approves Omeros’ YARTEMLEA® – …
SEATTLE -- (BUSINESS WIRE)--Dec. 24, 2025-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® …
US FDA approves Omeros' drug to treat dangerous transplant complication ...
1 day ago · The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication in adults and children two years and older, marking the first treatment …
FDA Approves Omeros’ YARTEMLEA - Business Wire
1 day ago · Omeros’ lead lectin pathway inhibitor YARTEMLEA ®, which inhibits the pathway’s effector enzyme MASP-2, is FDA-approved for the treatment of hematopoietic stem cell …
FDA Approves Narsoplimab-wuug for Transplant-Associated …
1 day ago · The FDA approved nasoplimab-wuug (Yartemlea; Omeros Corporation) for the treatment of patients with transplant-associated thrombotic microangiopathy (TA-TMA). …
Omeros Wins FDA Approval For YARTEMLEA In Transplant
1 day ago · (RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated …
FDA Approval of Omeros’ YARTEMLEA Establishes New Standard …
1 day ago · Omeros secures FDA approval for YARTEMLEA, the first and only therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The …
Omeros Gets FDA Approval of Yartemlea - MarketWatch
1 day ago · By Colin Kellaher Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants.
FDA Approves Omeros' Yartemlea, First Approved Drug For …
1 day ago · Omeros Corp. (OMER) said Thursday that the U.S. Food and Drug Administration has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell …
US FDA approves Omeros' drug to treat dangerous transplant complication
The drug, branded Yartemlea, is used to treat a condition known as transplant-associated thrombotic microangiopathy, or TA-TMA, a serious complication that can develop after stem …
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy …
1 day ago · Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the …